Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Equity Average (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Equity Average for 5 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Equity Average rose 28.67% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 28.67% year-over-year, with the annual reading at $1.1 billion for FY2025, 25.56% up from the prior year.
  • Equity Average hit $1.2 billion in Q4 2025 for Krystal Biotech, up from $1.1 billion in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.2 billion in Q4 2025 to a low of $413.4 million in Q3 2021.
  • Historically, Equity Average has averaged $722.5 million across 5 years, with a median of $704.5 million in 2023.
  • Biggest five-year swings in Equity Average: dropped 11.41% in 2023 and later soared 55.95% in 2024.
  • Year by year, Equity Average stood at $500.9 million in 2021, then rose by 6.11% to $531.5 million in 2022, then soared by 44.36% to $767.3 million in 2023, then rose by 19.4% to $916.1 million in 2024, then rose by 28.67% to $1.2 billion in 2025.
  • Business Quant data shows Equity Average for KRYS at $1.2 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.0 billion in Q2 2025.